MIT and IBM are launching the MIT-IBM Computing Research Lab, expanding their seven-year AI collaboration into quantum and hybrid computing systems to tackle real-world challenges like drug discovery, weather prediction, and financial forecasting.
The Zuckerberg Chan Biohub is committing $500 million over five years to build AI-powered simulations of the human body, partnering with Nvidia and top research institutions in an ambitious push to ultimately cure all human disease.
The UK government launches a $675 million Sovereign AI venture fund to invest in domestic startups across AI model development, agentic AI, and drug discovery, offering not just capital but supercomputer access, free visas, and government contracts to reduce dependence on foreign technology.
OpenAI launches GPT-Rosalind, a restricted life sciences AI model that outperforms 95% of human experts in RNA sequence prediction and surpasses other AI on science benchmarks, with access limited to approved organizations like Amgen and Moderna due to misuse concerns.
OpenAI launches GPT-Rosalind, a frontier AI model purpose-built for life sciences that outperforms human experts above the 95th percentile on RNA sequence-to-function tasks, beats competitors on key benchmarks, and is now available in research preview for U.S. Enterprise customers through partnerships with Amgen, Moderna, and the Allen Institute.
AWS launches Amazon Bio Discovery, an AI-powered platform that designed nearly 300,000 novel antibody molecules in collaboration with Memorial Sloan Kettering Cancer Center, slashing drug discovery timelines from up to a year down to just weeks.
AI is going deeply personal this week: Utah launches a pilot letting AI renew psychiatric prescriptions for just $19/month, OpenAI secures a record $122 billion funding round at an $852 billion valuation, and thousands of workers worldwide are filming their daily chores to train the next generation of humanoid robots.
Anthropic acquires stealth AI biotech startup Coefficient Bio in a $400 million stock deal, bringing the 10-person team behind an AI-driven drug discovery platform into its health and life sciences division, accelerating the company's growing push into healthcare.
Eli Lilly signs a landmark $2.75 billion deal with AI drug pioneer Insilico Medicine, offering $115 million upfront to fast-track AI-generated drugs across multiple disease areas into global markets.
NVIDIA CEO Jensen Huang declares AI infrastructure the largest buildout in human history, requiring trillions in investment across a five-layer stack of energy, chips, infrastructure, models, and applications, as open source models accelerate adoption and industries from drug discovery to robotics begin generating measurable economic value.